30 June 2020

Meeting report - DDS2020 Digital

The PVRI 7th Annual Drug Discovery & Development Symposium for Pulmonary Hypertension, originally scheduled to take place in Boston, USA, was presented digitally following the COVID-19 pandemic on 29 June 2020.

IMG_0539.JPG

Our scientific organisers set an exciting programme of featured presentations, which were released over a five-day period from 24-28 June 2020, and were culminated by a live webinar on 29 June.

Digital format proves its success

Nearly 220 participants joined the session and were able to ask and upvote questions, participate in polls and download slides.

Professor Paul Hassoun, Johns Hopkins University School of Medicine, USA, Professor Allan Lawrie, University of Sheffield, UK, and Dr Anna Hemnes, Vanderbilt University Medical Center, USA, moderated the following talks: 

  • Clinical development of inhaled GB002 for the treatment of pulmonary arterial hypertension, sponsored by Gossamer Bio.
    Presented by Professor Ardeschir Ghofrani, Justus-Liebig-University Giessen, Germany, whose presentation received an average score of 9/10 
  • A study of sotatercept for the treatment of pulmonary arterial hypertension (PULSAR, NCT03496207), sponsored by Acceleron
    Presented by Dr David Badesch, University of Colorado, USA, whose presentation received a score of 9/10 
  • Pharmacogenomics and placebo response in a randomised clinical trial
    Presented by Dr Kathryn Hall, Brigham and Women's Hospital, Harvard Medical School, USA, whose presentation received a score of 9/10 

The delivery of the new format of the virtual meeting received an overall score of 9/10.

This was a fantastic event with great technology, and it managed to convey the excitement of true scientific debate much better than other webinars I have attended.
Paul Corris PVRI Chair of the Board of Trustees, UK
I just watched the drug symposium live webinar, which was outstanding. All three presentations were excellent. I particularly enjoyed Kathryn Hall’s talk which gave a novel perspective on placebos. Having attended several of these online events over the past few months, this was hands down the finest of all from a technical standpoint.
Stuart Rich PVRI Trustee, USA


Comments (0)

Our research platform is the world.

Through worldwide collaboration, we can begin to answer the question of a global disease.

Join the PVRI
standard-example-image.jpg